Brief: Caribou Biosciences To Evaluate Strategic Alternatives
06/10/2026 21:20
BRIEF-Caribou Biosciences To Evaluate Strategic Alternatives Caribou Biosciences, Inc. CRBU.O:
CARIBOU BIOSCIENCES TO EVALUATE STRATEGIC ALTERNATIVES
CARIBOU BIOSCIENCES - TO DISCONTINUE VISPA-CEL AND CB-011 CAR-T CELL THERAPY PROGRAMS
CARIBOU BIOSCIENCES - TO IMPLEMENT WORKFORCE AND COST REDUCTIONS
CARIBOU BIOSCIENCES - PLANS SUBSTANTIAL WORKFORCE REDUCTION EXPECTED TO BE MOSTLY COMPLETE IN Q4 2026
CARIBOU BIOSCIENCES - REPORTS CASH AND SECURITIES OF $113.80 MILLION AS OF JUNE 30, 2026
Source text: ID:nGNXF64mr
Further company coverage: CRBU.O